

# Lithea presents promising preclinical data at Lund University Cancer Centre's World Cancer Day event

Lithea announces that its Chief Medical Officer Dr. Mathias Lidgren and Chief Technology Officer Dr. Deepak Raina participated in the Lund University Cancer Centre World Cancer Day event, where they presented new preclinical data supporting the potential of LIT1001 as an add-on to the current MAP regimen for osteosarcoma.

During the session, Dr Lidgren and Dr Raina shared results from a recent mice study demonstrating that LIT1001 combined with MAP achieved superior tumour control compared to MAP alone, with stronger tumour-growth inhibition and sustained local efficacy. The combination also maintained a favourable tolerability profile, reflecting the targeted intratumoral release mechanism of LIT1001.

“These findings strengthen the case for LIT1001 as a meaningful enhancement to standard osteosarcoma therapy,” said Lithea’s CMO. “Our goal is to bring a new level of precision to chemotherapeutic delivery while supporting better outcomes for patients who urgently need new options.”



From Left: Dr. Mathias Lidgren, Dr. Deepak Raina.

The data presented aligns with Lithea’s development strategy for a planned first-in-human program and highlights the company’s growing traction within the oncology innovation ecosystem.

For more information about Lithea, please contact:  
Ludvig Sjöberg, CEO  
[ludvig.sjoberg@lithea-pharma.com](mailto:ludvig.sjoberg@lithea-pharma.com)

February 6, 2026  
Lund, Sweden

## Lithea AB

Kung Oskars väg 11C, 222 35, Lund, Sweden  
[www.lithea-pharma.com](http://www.lithea-pharma.com)



## **About Lithea**

*Lithea is a pharma startup company developing innovative treatment options for cancer. Our mission is to prolong the lives of cancer patients. Lithea's patented technology platform is based on research done by the founders of the company at Lund University for using bone minerals as a drug delivery system of anticancer substances to solid tumour cancer patients. Our first lead asset under development is called LIT1001 and it is for targeted treatment of osteosarcoma tumours. For more information, please visit [www.lithea-pharma.com](http://www.lithea-pharma.com).*

### **Lithea AB**

Kung Oskars väg 11C, 222 35, Lund, Sweden  
[www.lithea-pharma.com](http://www.lithea-pharma.com)